Corporate Presentation June 2024 Forward Looking Statements This presentation is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities of Beyond Air, Inc. (the "Company") nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The Compan ...

Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Conference Call February 12, 2024 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler Les Sulewski - Truist Yale Jen - Laidlaw & Company Sam Eiber - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good afternoon, and welcome, everyone, to the Beyond Air Financial Results Call for the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or other ju ...

Beyond Air, Inc. (NASDAQ:XAIR) Q2 2024 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jeremy Jacoby - Truist Securities Marie Thibault - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or other j ...

产品与技术 - Beyond Air的LungFit® PH是首个获得FDA批准的系统，能够使用室内空气生成和交付无限的按需一氧化氮[24] - LungFit® PH的智能过滤器每12小时更换一次，确保医院仅为实际使用的气体付费[27] - 公司在自家产品的临床试验中，低浓度一氧化氮（≤80 ppm）用于新生儿低氧呼吸衰竭的治疗[15] - 高浓度一氧化氮（80至400 ppm）用于医院设置中的抗微生物治疗，包括COVID-19和支气管炎[15] - 150 ppm NO的治疗在三项试验中普遍安全且耐受性良好，所有组别的不良事件发生率相似[38] - 研究显示，使用高浓度NO治疗住院婴儿急性支气管炎具有良好的长期安全性[41] - 研究表明，使用高浓度NO的间歇性给药方案可以在不产生负面副作用的情况下安全地进行[35] - 研究结果显示，使用LungFit® PRO的iNO治疗在不良事件方面表现良好，未因不良事件或不适而中止治疗[47] 市场机会与展望 - 预计PPHN的市场机会超过3.5亿美元，年住院病例为15,000例[16] - 公司在全球范围内的市场机会超过350亿美元，涵盖多种肺部疾病和癌症治疗[16] - 预计到2025年，自闭症谱系障碍的护理成本将超过4600亿美元[17] - Nitric Oxide (NO)在2022年被认为是一个超过370亿美元的检查点抑制剂市场[67] 临床研究与数据 - 公司在2023年下半年计划提交持久性肺动脉高压（PPHN）和病毒性社区获得性肺炎（VCAP）的临床研究[15] - 预计在2024年启动慢性阻塞性肺病（COPD）患者的高浓度一氧化氮临床试验[15] - 超过5000名患者接受了高浓度一氧化氮(NO)治疗，涉及170多个不同的临床环境[33] - 在一项长期安全性研究中，85 ppm NO + 标准支持治疗组的再入院率为4.17%，而160 ppm NO + 标准支持治疗组的再入院率为11.11%[40] - 研究中，NTM细菌在美国25个州的水样中几乎占到80%[50] 财务状况 - 截至2023年6月30日，公司的股价为4.26美元，流通股数为3000万股[88] - 公司的现金及现金等价物为5700万美元，债务为1750万美元，预计季度烧钱约为1000万美元[88] - 公司拥有超过15项专利，预计到2040年到期，且有超过10项待审专利申请，若获批可延长至2044年[88] 研发与合作 - 公司与希伯来大学合作，获得了几种部分抑制神经元一氧化氮合酶(nNOS)活性的化合物的全球独占商业权利[79] - 预计2024年上半年将启动针对自闭症的第一阶段临床研究[91] - 2023年下半年将宣布美国社区获得性肺炎（VCAP）研究的顶线数据[89]

Beyond Air, Inc. (NASDAQ:XAIR) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Marie Thibault - BTIG Scott Henry - ROTH Capital Jason Bednar - Piper Sandler Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Company Operator Good afternoon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or other jurisd ...

Beyond Air, Inc. (NASDAQ:XAIR) Q4 2023 Earnings Conference Call June 22, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Company Suraj Kalia - Oppenheimer Operator Good afternoon, and welcome everyone to the Beyond Air Financial Results Call f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) Delaware 47-3812456 (State or other jurisdiction (I.R.S. Employer of incorporation or organiz ...